Karachi: BF Biosciences Limited has announced that a meeting of its Board of Directors is set to take place on April 28, 2025. The meeting will be conducted via video link and will focus on reviewing the quarterly accounts for the period ending March 31, 2025. The board will also consider the declaration of any entitlements.

In compliance with the Pakistan Stock Exchange (PSX) regulations, the company has instituted a closed period from April 21, 2025, to April 28, 2025. During this time, no director, CEO, or executive of BF Biosciences Limited will be permitted to engage in any form of share dealings, either directly or indirectly. This measure adheres to section 5.6.1(d) of the PSX Regulations to ensure transparency and avoid any potential conflicts of interest.

According to information available from the Pakistan Stock Exchange (PSX), TRE Certificate Holders of the Exchange have been informed about the upcoming board meeting and the closed period. This update is crucial for stakeholders and investors who monitor the market category of pharmaceuticals and biotechnology, as it provides clarity on the company's governance practices.

BF Biosciences Limited continues to maintain adherence to regulatory requirements, reflecting its commitment to transparent corporate governance. The company's financial performance and any potential entitlements for investors will be further discussed in the forthcoming board meeting.